Search Result

Results for "

CB2 cannabinoid receptors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cannabinoid Receptor (94) Aldehyde Dehydrogenase (ALDH) (1) ANGPTL (1) Apoptosis (3) Biochemical Assay Reagents (1) Caspase (2) Cholinesterase (ChE) (2) Cytochrome P450 (5) DAGL (1) Drug Intermediate (1) Drug Isomer (1) Endogenous Metabolite (16) Environmental Pollutants (1) FAAH (2) Fungal (2) GPR55 (3) HIF/HIF Prolyl-Hydroxylase (2) Interleukin Related (3) Isotope-Labeled Compounds (6) PDK-1 (1) PERK (1) Potassium Channel (1) PPAR (2) Reactive Oxygen Species (ROS) (1) Reference Standards (4) Tau Protein (2) TNF Receptor (2) TRP Channel (5) VEGFR (1)
By Research Areas:	Cancer (11) Cardiovascular Disease (1) Endocrinology (1) Infection (2) Inflammation/Immunology (27) Metabolic Disease (18) Neurological Disease (62)
Click Chemistry:	Azide (1)

103

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Cannabinoid Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10863

Anandamide 2 Publications Verification AEA; Arachidonoyl ethanolamide	Cannabinoid Receptor PPAR TRP Channel GPR55 Fungal Tau Protein Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Inflammation/Immunology
Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and *CB2). Anandamide can activate numerous other receptors* like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .

HY-100197

Synaptamide 1 Publications Verification N-Docosahexaenoyl ethanolamine (DHEA); Docosahexaenoyl ethanolamide	Cannabinoid Receptor	Neurological Disease
Synaptamide (Dehydroepiandrosteron; DHEA) is an endogenous metabolite and structural analogue of Anandamide. Synaptamide binds to both the cannabinoid-1 and 2 (CB1 and CB2) cannabinoid receptors and has anti-inflammatory properties. Synaptamide is the first small-molecule endogenous ligand of an adhesion G protein-coupled receptor (aGPCR) .

HY-15451

MDA 19 2 Publications Verification BZO-HEXOXIZID	Cannabinoid Receptor	Neurological Disease
MDA 19 is a potent and selective agonist of human **cannabinoid receptor 2 (CB2), with a K_i** of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity .

HY-W008364

Olivetol	Cytochrome P450 Cannabinoid Receptor	Neurological Disease
Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors CB1 and *CB2* . Olivetol also inhibits CYP2C19 and CYP2D6 activity, with IC₅₀s of 15.3 μM, 7.21 μM and K_is of 2.71 μM, 2.87 μM, respectively .

HY-103325

JTE-907	Cannabinoid Receptor TRP Channel Interleukin Related ANGPTL VEGFR	Metabolic Disease Inflammation/Immunology
JTE-907 is a selective and orally active cannabinoid *CB2* receptor inverse agonist and exerts anti-inflammatory effects. JTE-907 upregulates IL-6, MCP-1, IL-1β, VEGF, ANGPTL4, and TRPV1 in mature adipocytes. JTE-907 downregulates CB1, MCP-1, and IL-1β in preadipocytes. JTE-907 inhibits ear swelling in mice. JTE-907 reverses the protective effects of CB2 agonists and Anandamide (HY-10863) against cytokine-evoked colonic mucosal damage. JTE-907 can be used for the research of allergic dermatitis, obesity, and colitis .

HY-10871

Otenabant 2 Publications Verification CP-945598	Cannabinoid Receptor	Metabolic Disease
Otenabant is a potent and selective cannabinoid receptor CB1 antagonist with K_i of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

HY-14167

GW842166X	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
GW842166X is a potent and selective cannabinoid receptor 2 (CB2) agonist with IC₅₀ values of 63 and 91 nM for human and rat CB2, respectively.

HY-100488

Bay 59-3074	Cannabinoid Receptor	Cancer
Bay 59-3074 is a selective cannabinoid **CB₁/CB₂ receptor partial agonist with K_i values of 48.3 and 45.5 nM at human CB₁ and CB₂** receptors, respectively. Bay 59-3074 has analgesic properties .

HY-111110

Olorinab 2 Publications Verification APD 371	Cannabinoid Receptor	Neurological Disease
Olorinab (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 *(CB₂)* agonist, with an EC₅₀ of 6.2 nM for hCB₂.

HY-110036

GW-405833 L768242	Cannabinoid Receptor Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase TNF Receptor Interleukin Related	Neurological Disease Inflammation/Immunology
GW-405833 (L768242) is a potent, selective cannabinoid receptor 2 (CB₂) agonist. GW405833 has EC₅₀ and K_i values of 0.65 nM and 3.92 nM for *CB₂, and EC₅₀* and K_i values of 16.1 μM and 4772 nM for CB₁. GW-405833 also exhibits non-competitive CB₁ antagonist, exerting its analgesic and and anti-inflammatory effect through a CB₁ receptor (rather than *CB₂) dependent mechanism. GW-405833 can significantly inhibit the production of cAMP* stimulated by Forskolin (HY-15371). GW405833 inhibits glycolysis by down-regulating HIF-1α, thereby alleviating acute liver failure (ALF) .

HY-14791

Ibipinabant 1 Publications Verification SLV319; BMS-646256	Cannabinoid Receptor	Metabolic Disease
Ibipinabant (SLV319) is a potent, selective and orally active antagonist of **cannabinoid CB1 receptor, with a K_i** of 7.8 nM. Ibipinabant shows more than 1000-fold selectivity for CB1 over CB2 (K_i=7943 nM). Ibipinabant can be used for the research of obesity and diabetic .

HY-110050

GP1a	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
GP1a is a potent agonist of cannabinoid receptor 2 (CB2). Gp1a is beneficial to skin wound healing. GP1a inhibits inflammation and fibrogenesis while promoting re-epithelialization .

HY-W005629

Leelamine	Environmental Pollutants Cannabinoid Receptor PDK-1	Metabolic Disease Cancer
Leelamine is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor with an IC₅₀ value of 9.5 μM, showing a blood glucose lowering effect in the diabetic mouse. Leelamine is also a weak agonist of cannabinoid receptors CB1 and *CB2. Leelamine decreases mitotic activity, prostate-specific antigen expression and induces Apoptosis* to cell death in cancer cells .

HY-112340

CB1 antagonist 4	Cannabinoid Receptor	Neurological Disease Metabolic Disease
CB1 antagonist 4 (compound 8) is a selective cannabinoid receptor 1 (CB1) inverse agonist with an IC₅₀ of 8.5 nM for human CB1. CB1 antagonist 4 shows selective for CB1 over CB2 receptors (IC₅₀ of 604.9 nM). CB1 antagonist 4 inhibits GTP binding to CB1-overexpressing cell membranes with an EC₅₀ of 18.5 nM .

HY-132217

CB2 receptor agonist 2	Cannabinoid Receptor	Neurological Disease
CB2 receptor agonist 2 is a potent and selective agonist for the *CB2* (cannabinoid type 2) receptor with a K_i of 8.5 nM. CB2 receptor agonist 2 has high affinity and selectivity for *CB2* .

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a cannabinoid (CB) receptor agonist with K_is of 857 nM and 598 nM for human recombinant CB1 and **CB2 receptors**, respectively .

HY-119104

AZD1940 1 Publications Verification	Cannabinoid Receptor	Neurological Disease
AZD1940 is an orally active, high affinity **cannabinoid CB1/CB2 receptor agonist with pK_i values of 7.93 and 9.06 for human CB1R and CB2R**, respectively. AZD1940 shows a robust analgesia action .

HY-146134

PGN36	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
PGN36 is a selective **cannabinoid CB2 receptor (CB2R) antagonist with K_i*s of 0.09 µM and >40 µM for CB2*R and CB1R, respectively. PGN36 abolishes the increase in collagen type I gene expression by the inducer of bone activity. PGN36 is able to cross the blood-brain barrier. PGN36 can be used for the study of frontotemporal dementia (FTD) .

HY-120851

O-7460	Cannabinoid Receptor DAGL	Metabolic Disease
O-7460 is a potent and selective DAGLα inhibitor, with an IC₅₀ of 0.69 μM. O-7460 shows selectivity over onoacylglycerol lipase (MAGL), human CB1 and CB2 cannabinoid receptors. O-7460 can decrease HFD-caused an up-regulation of 2-AG levels .

HY-113421

Linoleoyl ethanolamide Linoleic acid monoethanolamide	Cannabinoid Receptor	Neurological Disease
Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of ^[3H]CP-55,940 with K_is of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .

HY-124283A

LEI-101	Cannabinoid Receptor	Neurological Disease
LEI-101 is a potent, selective, and orally bioavailable **cannabinoid CB2 receptor** agonist, with a pEC₅₀ of 8 for hCB2, and a pK_i of less than 4 for hERG. LEI-101 is ~100-fold more potent in binding to CB2 receptors than to CB1 receptors .

HY-131004

CB2R PAM	Cannabinoid Receptor	Neurological Disease
CB2R PAM is an orally active **cannabinoid type-2 receptors (CB2Rs)** positive allosteric modulator. CB2R PAM displays antinociceptive activity in vivo in an experimental mouse model of neuropathic pain .

HY-145153

S-777469	Cannabinoid Receptor	Neurological Disease
S-777469 is a selective and orally available cannabinoid type 2 receptor *(CB2)* agonist with a K_i of 36 nM. S-777469 significantly suppresses compound 48/80-induced scratching behavior in mice in a dose-dependent manner. S-777469 produces its antipruritic effects by inhibiting itch signal transmission through CB2 agonism .

HY-150029

CB1/2 agonist 3	Cannabinoid Receptor	Neurological Disease
CB1/2 agonist 3 (compound 52), a potent non-selective cannabinoid ligand, is a *CB1/CB2* (cannabinoid receptor) competitive agonist. CB1/2 agonist 3 acts on hCB1 and hCB2 with K_i values of 5.9 nM and 3.5 nM, respectively .

HY-122964

URB447	Cannabinoid Receptor	Metabolic Disease
URB447 is a peripherally restricted CB₁ cannabinoid antagonist (IC₅₀: 313 nM and 41 nM for rat CB1 and human CB2 receptor respectively ). URB447 lowers food intake and body-weight gain in mice without entering the brain or antagonizing central CB₁-dependent responses. URB447 can be used for research of obesity .

HY-10863S

Anandamide-d8 AEA-d₈	Isotope-Labeled Compounds Cannabinoid Receptor PPAR Endogenous Metabolite Tau Protein GPR55 Fungal TRP Channel	Infection
Anandamide-d8 is a deuterated labeled Anandamide . Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and *CB2). Anandamide can activate numerous other receptors* like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .

HY-14900

Tedalinab 1 Publications Verification GRC-10693	Cannabinoid Receptor	Inflammation/Immunology
Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 *(CB2)* agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment .

HY-134173

Arachidonoyl ethanolamide phosphate	Cannabinoid Receptor Apoptosis	Neurological Disease
Arachidonoyl ethanolamide phosphate, an endocannabinoid, is an endogenous ligand for cannabinoid receptors in the central nervous system (CB1 subtype) and peripheral immune cells (CB2 subtype) .

HY-124089

Eicosapentaenoyl ethanolamide	Cannabinoid Receptor	Metabolic Disease
Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is **cannabinoid CB1/CB2 receptor** agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant .

HY-113421S

Linoleoyl ethanolamide-d4	Isotope-Labeled Compounds Cannabinoid Receptor	Neurological Disease
Linoleoyl ethanolamide-d4 is a deuterated labeled Linoleoyl ethanolamide . Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of ^[3H]CP-55,940 with K_is of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .

HY-10871A

Otenabant Hydrochloride CP 945598 Hydrochloride	Cannabinoid Receptor	Metabolic Disease
Otenabant Hydrochloride is a potent and selective cannabinoid receptor CB1 antagonist with K_i of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

HY-152251

CB2R/FAAH modulator-1	Cannabinoid Receptor FAAH	Inflammation/Immunology
CB2R/FAAH modulator-1 is a **cannabinoid type 2 receptor (CB2R) full agonist with K_i*s of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH* modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production .

HY-110065

SER-601	Cannabinoid Receptor	Neurological Disease
SER-601 is a potent and selective peripheral cannabinoid (CB2) receptor agonist with a K_i of 6.3 nM. SER-601 has analgesic and antidiabetic properties and can be used for relevant research .

HY-152581

CB2R antagonist 3	Cannabinoid Receptor	Inflammation/Immunology
CB2R antagonist 3 is a selective antagonist of **cannabinoid type 2 receptor (CB2R)*. CB2R antagonist 3 has high affinity for human CB2R and specific selectivity for CB1R. CB2R antagonist 3 can be combined with CB65 (HY-110047), the activator of CB2R. CB2*R antagonist 3 effectively up-regulates the expression of anti-inflammatory cytokines and down-regulates the expression of pro-inflammatory cytokines .

HY-110036A

GW405833 hydrochloride L768242 hydrochloride	Cannabinoid Receptor Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase TNF Receptor Interleukin Related	Neurological Disease Inflammation/Immunology
GW405833 (L768242) hydrochloride is a potent, selective cannabinoid receptor 2 (CB₂) agonist. GW405833 has EC₅₀ and K_i values of 0.65 nM and 3.92 nM for *CB₂, and EC₅₀* and K_i values of 16.1 μM and 4772 nM for CB₁. GW405833 hydrochloride also exhibits non-competitive CB₁ antagonist, exerting its analgesic effect through a CB₁ receptor (rather than *CB₂) dependent mechanism. GW405833 hydrochloride can significantly inhibit the production of cAMP* stimulated by Forskolin (HY-15371). GW405833 hydrochloride inhibits glycolysis by down-regulating HIF-1α, thereby alleviating acute liver failure (ALF) .

HY-110194

Virodhamine TFA	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine TFA is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine TFA induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine TFA can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases .

HY-178943

Neuroprotective agent 15	Cholinesterase (ChE) Cannabinoid Receptor Aldehyde Dehydrogenase (ALDH) Caspase Apoptosis	Neurological Disease
Neuroprotective agent 15 (Compound 3e) is a neuroprotective agent. Neuroprotective agent 15 is a selective butyrylcholinesterase (BChE) inhibitor, with IC₅₀ values of 2.6 and 114.3 μM for BChE and AChE respectively. Neuroprotective agent 15 has cannabinoid CB2 receptor (CB2 *receptor) agonistic activity. Neuroprotective agent 15 can reduce cell death, LDH* release and Caspase-3/7 activity, and inhibit apoptosis. Neuroprotective agent 15 can reduce the formation of superoxide free radicals, maintain cell morphology, and significantly lower oxidative stress levels. Neuroprotective agent 15 can be used in the research of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease .

HY-W127407

Glycerophospho-N-arachidonoyl ethanolamine	Biochemical Assay Reagents	Others
Glycerophospho-N-Arachidonoyl Ethanolamine is a N-acylated ethanolamines (NAEs). Most NAEs are naturally occurring lipids with diverse biological activities. Different types of NAE can be derived from glycerophosphate-linked precursors through the activity of glycerophosphodiesterase 1 (GDE1). Glycerophosphate-N-Arachidonoyl Ethanolamine is the precursor of Anandamide (AEA), also known as Anandamide. AEA is an endocannabinoid neurotransmitter that binds to central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. It inhibits the specific binding of [3H]-HU-243 to synaptosomal membranes with a Ki value of 52 nM compared to 46 nM for δ9-THC.

HY-173083

MDA7	Cannabinoid Receptor	Neurological Disease
MDA7 is the selective agonist for cannabinoid receptor 2 with EC₅₀ of 128 nM and 67.4 nM in human CB2 receptor and rat CB2 receptor. MDA7 exhibits good affinity to human CB2 receptor and rat CB2 receptor with K_i of 422 nM and 238 nM. MDA7 exhibits analgesic activity in rats models .

HY-128040

Virodhamine hydrochloride	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine (hydrochloride) is a cannabinoid CB1 receptor partial agonist and cannabinoid *CB2* receptor full agonist .

HY-168734

CB2 receptor agonist 9	Cannabinoid Receptor	Inflammation/Immunology
CB2 receptor agonist 9 (Compound 33) is an orally active agonist for cannabinoid receptor 2 (CB2 *receptor) with an EC₅₀* of 16.2 nM. CB2 receptor agonist 9 inhibits the expression of TNF-α, IL-1β and IL-6, exhibits anti-inflammatory efficacy in DDS (HY-116282)-induced mouse acute colitis model .

HY-W751734

HU 433	Cannabinoid Receptor	Others Neurological Disease Inflammation/Immunology
HU 433 is a synthetic cannabinoid *CB2* receptor agonist and is the enantiomer of HU 308 (HY-161510). HU 433 exerts its anti-inflammatory and neuroprotective effects by binding to *CB2* receptors. HU 433 can be used in the study of neuroinflammation and retinal diseases .

HY-175730

CB2R ligand-1	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology Cancer
CB2R ligand-1 (Compound L14) is a selective **Cannabinoid type 2 receptor (CB2R) ligand with a with K_i** of 0.16  nM for CB2R over CB1R. CB2R ligand-1 as be used as a tracer for positron emission tomography (PET) imaging of neurodegenerative diseases, inflammation and cancer .

HY-133533

O-2050	Cannabinoid Receptor	Neurological Disease
O-2050 is a high affinity **cannabinoid CB₁ receptor antagonist with a K_i** of 2.5 nM. O-2050 inhibits cannabinoid CB₂ receptor (K_i=0.2 nM). O-2050 can cause locomotor stimulation in mice .

HY-100778

SMM-189	Cannabinoid Receptor	Neurological Disease
SMM-189 is a potent and selective **cannabinoid receptor 2 (CB2)** inverse agonist. SMM-189 plays an important role in neurodegenerative disorders and traumatic brain injury research .

HY-152576

CB2R agonist 1	Cannabinoid Receptor	Inflammation/Immunology
CB2R agonist 1 is a selective ligand of cannabinoid receptor subtype 2 (CB2R) with an EC₅₀ value of 0.56 µM. CB2R agonist 1 has high affinity and excellent selectivity for human *CB2R* and CB1R respectively. CB2R agonist 1 regulates the production of pro-inflammatory cytokines and anti-inflammatory cytokines and play an immunomodulatory role .

HY-163825

RNB-61	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
RNB-61 is an oral active agonist of cannabinoid CB2 receptor (CB2R), with the K_i ranging from 0.13 nM to 1.81 nM. RNB-61 has nephroprotective and/or antifibrotic effects. RNB-61 has negligible penetration into the brain .

HY-172568

(±)5(6)-EET Ethanolamide	Cannabinoid Receptor Cytochrome P450	Neurological Disease Inflammation/Immunology
(±)5(6)-EET Ethanolamide is a metabolite of Anandamide (HY-10863) generated via oxidation by cytochrome P450 enzymes. (±)5(6)-EET Ethanolamide is also a selective cannabinoid receptor 2 (CB2) agonist. (±)5(6)-EET Ethanolamide has K_i values of 11.4 μM and 8.9 nM for human CB1 and *CB2*, respectively . (±)5(6)-EET Ethanolamide can be used in research on immunomodulation and neuroinflammation .

HY-110041

L-759656	Cannabinoid Receptor	Inflammation/Immunology
L-759656 is a selective **cannabinoid CB2** receptor agonist, with the K_i of 11.8 nM for the human CB2 receptor. L-759656 potently inhibits Forskolin (HY-15371)-stimulated cyclic AMP production in Chinese Hamster Ovary (CHO) cells, with an EC₅₀ of 3.1 nM. L-759656 can be used for the study of immune-related diseases and inflammatory diseases .

HY-123410

KM-233	Cannabinoid Receptor	Cancer
KM-233 is a classical cannabinoid with good blood brain barrier penetration. KM-233 possesses a selective affinity for the CB2 receptors relative to THC. KM-233 is effective at reducing U87 glioma tumor burden, and can be used for glioma research .

Cat. No.	Product Name	Type

HY-W127407

Glycerophospho-N-arachidonoyl ethanolamine

Biochemical Assay Reagents

Glycerophospho-N-Arachidonoyl Ethanolamine is a N-acylated ethanolamines (NAEs). Most NAEs are naturally occurring lipids with diverse biological activities. Different types of NAE can be derived from glycerophosphate-linked precursors through the activity of glycerophosphodiesterase 1 (GDE1). Glycerophosphate-N-Arachidonoyl Ethanolamine is the precursor of Anandamide (AEA), also known as Anandamide. AEA is an endocannabinoid neurotransmitter that binds to central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. It inhibits the specific binding of [3H]-HU-243 to synaptosomal membranes with a Ki value of 52 nM compared to 46 nM for δ9-THC.

Cat. No.	Product Name	Target	Research Area

HY-P11831

RD-pepcan-11	Cannabinoid Receptor PERK	Inflammation/Immunology
RD-pepcan-11 is a CB1 receptor agonist. RD-pepcan-11 increases the relative phosphorylation level of ERK1/2. RD-pepcan-11 mediates analgesic effects through interaction with CB1 receptors in a carrageenan-induced mouse inflammatory pain model. RD-pepcan-11 can be used in studies related to inflammatory pain .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-10863

Anandamide 2 Publications Verification AEA; Arachidonoyl ethanolamide	Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Cannabinoid Receptor PPAR TRP Channel GPR55 Fungal Tau Protein Endogenous Metabolite
Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and *CB2). Anandamide can activate numerous other receptors* like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .

HY-W008364

Olivetol	Microorganisms other families Phenols Polyphenols Plants Source Classification	Cytochrome P450 Cannabinoid Receptor
Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors CB1 and *CB2* . Olivetol also inhibits CYP2C19 and CYP2D6 activity, with IC₅₀s of 15.3 μM, 7.21 μM and K_is of 2.71 μM, 2.87 μM, respectively .

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Endogenous metabolite Disease Research Fields Source Classification	Cannabinoid Receptor Endogenous Metabolite
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a cannabinoid (CB) receptor agonist with K_is of 857 nM and 598 nM for human recombinant CB1 and **CB2 receptors**, respectively .

HY-113421

Linoleoyl ethanolamide Linoleic acid monoethanolamide	Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Cannabinoid Receptor
Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of ^[3H]CP-55,940 with K_is of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .

HY-134615

Mead ethanolamide	Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Endogenous metabolite Disease Research Fields Source Classification	Cannabinoid Receptor Endogenous Metabolite
Mead ethanolamide is an endogenous **cannabinoid receptor agonist with K_d values of 753 nM and 1810 nM against CB1 and CB2**, respectively .

HY-N6097

Amauromine	Alkaloids Microorganisms Indole Alkaloids Source Classification	Cannabinoid Receptor
Amauromine is a peripheral selective cannabinoid receptor type 1 (CB1) receptor antagonist with K_i and K_b values of 178 nM and 66.6 nM, respectively .

HY-W008364R

Olivetol (Standard)	Structural Classification Microorganisms other families Phenols Polyphenols Plants Source Classification	Reference Standards Cytochrome P450 Cannabinoid Receptor
Olivetol (Standard) is the analytical standard of Olivetol. This product is intended for research and analytical applications. Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors CB1 and CB2 . Olivetol also inhibits CYP2C19 and CYP2D6 activity, with IC50s of 15.3 μM, 7.21 μM and Kis of 2.71 μM, 2.87 μM, respectively .

HY-N19807

Dodec-2E-ene-8,10-diynoic acid isobutylamide	Structural Classification Natural Products Cannabis sativa L Plants Moraceae Source Classification	Cannabinoid Receptor
Dodec-2E-ene-8,10-diynoic acid isobutylamide is an alkamide found in Echinacea angustifolia that binds to CB₁ (rat K_i = 61.1 μM) and *CB₂* (mouse K_i = 47.2 μM) **cannabinoid receptors**. Dodec-2E-ene-8,10-diynoic acid isobutylamide can be used in research on inflammatory diseases .

HY-121557

OMDM-1	Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Phenols Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
OMDM-1 is a potent, selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i of 2.4 μM .

HY-135880A

OMDM-4	Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Phenols Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
OMDM-4 is a selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i 17.7 μM .

HY-135882

OMDM-6	Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Phenols Endogenous metabolite Disease Research Fields Source Classification	TRP Channel Cannabinoid Receptor Endogenous Metabolite
OMDM-6 is a hybrid agonist of *vanilloid receptor* type 1 (VR1, TRPV1) (EC₅₀*=75 nM) and cannabinoid* receptor type 1 (CB1) (K_i=3.2 μM). OMDM-6 inhibits anandamide cellular uptake (ACU) with a K_i of 7.0 μM .

HY-135881

OMDM-5	Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Phenols Endogenous metabolite Disease Research Fields Source Classification	TRP Channel Endogenous Metabolite
OMDM-5 is a selective inhibitor of anandamide cellular uptake (ACU), with a K_i of 4.8 μM. OMDM-5 is also a potent *vanilloid receptor* type 1 (VR1, TRPV1) agonist, with an EC₅₀** of 75 nM, and shows weakly active as cannabinoid receptor type 1 (CB1) ligand (K_i=4.9 μM) .

HY-135880

OMDM-3	Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Phenols Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
OMDM-3 is a selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i of 16.6 μM .

HY-103342

OMDM-2	Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Phenols Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
OMDM-2 is a potent, selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i of 3.0 μM .

Cat. No.	Product Name	Chemical Structure

HY-10863S

Anandamide-d8

Anandamide-d8 is a deuterated labeled Anandamide . Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .

HY-113421S

Linoleoyl ethanolamide-d4

Linoleoyl ethanolamide-d4 is a deuterated labeled Linoleoyl ethanolamide . Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of ^[3H]CP-55,940 with K_is of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time .

HY-10863S1

Anandamide-d11
Anandamide-d₁₁ is deuterium labeled Anandamide. Anandamide is an immune modulator in the central nervous system acts via not only cannabinoid receptors (CB1 and CB2) but also other targets (e.g., GPR18/GPR55) .

HY-W008364S1

Olivetol-d9
Olivetol-d₉ is the deuterium labeled Olivetol. Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors CB1 and CB2[3]. Olivetol also inhibits CYP2C19 and CYP2D6 activities.

HY-124089S

Eicosapentaenoyl ethanolamide-d4

Eicosapentaenoyl ethanolamide-d₄ is the deuterium labeled Eicosapentaenoyl ethanolamide. Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is cannabinoid CB1/CB2 receptor agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant .

HY-W770198

2-Linoleoyl glycerol-d5

2-Linoleoyl glycerol-d₅ (2-Monolinolein-d₅; 2-Monolinoleoylglycerol-d₅) is the deuterium labeled 2-Linoleoyl glycerol (HY-130311). 2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid CB1 receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) .

Cat. No.	Product Name		Classification

HY-155481

CB2 receptor antagonist 3		Azide
CB2 receptor antagonist 3 (compound (S)-1) is an inverse agonist of the cannabinoid receptor CB2R with Kd=39 nM. CB2 receptor antagonist 3 can be used as a tool to synthesize a variety of CB2R probes .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CB2 cannabinoid receptors

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products